Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 870 across all filing types
Latest filing 2024-04-26 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司独立董事工作制度
Governance Information Classification · 95% confidence The document is titled '独立董事工作制度' which translates to 'Independent Director Work System'. It details the rules, responsibilities, nomination, election, and legal liabilities of independent directors in the company. It references company law, securities law, and regulatory requirements from the China Securities Regulatory Commission (CSRC) and Shanghai Stock Exchange. The content is a governance framework document outlining internal rules and governance practices related to the board of directors, specifically independent directors. It does not contain financial statements, earnings data, or audit results. It is not an announcement or a brief notice but a detailed governance policy document. Therefore, the document fits the category of Governance Information (CGR). The document length (8385 characters) supports it being a full governance report rather than a short announcement or notice.
2024-04-26 Chinese
西部证券股份有限公司关于圣湘生物科技股份有限公司2023年度募集资金存放与使用情况的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from the sponsor (西部证券股份有限公司) on the annual status of the company's (圣湘生物科技股份有限公司) use and management of funds raised from its initial public offering (IPO) on the STAR Market (科创板). It includes specifics on the amount raised, usage, balance, investment projects, cash management, and compliance with regulatory requirements. The document also contains an auditor's verification report on the annual fund usage and storage. The content focuses exclusively on the annual review of the use of IPO proceeds and related regulatory compliance, which aligns with the category of Audit Report / Information (AR) rather than a full Annual Report (10-K) or other categories. The document length (7721 characters) and detailed financial and regulatory content support this classification. Therefore, the filing type is AR with high confidence. FY 2023
2024-04-26 Chinese
圣湘生物科技股份有限公司第二届监事会2024年第二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed by the Supervisory Board of 圣湘生物科技股份有限公司 during their 2024 second meeting. It includes approvals of various reports such as the 2023 Supervisory Board Work Report, the 2023 Annual Report and its summary, the 2023 ESG Report, the 2024 Q1 Report, and other governance and financial matters. The document references multiple reports that are published separately on the Shanghai Stock Exchange website, indicating this document itself is a meeting resolution announcement rather than the reports themselves. The document length is 3470 characters, which is relatively short and consistent with an announcement rather than a full report. The content focuses on board meeting decisions and approvals, which aligns with Board/Management Information filings. Therefore, the best classification is MANG (Board/Management Information).
2024-04-26 Chinese
中审众环会计师事务所（特殊普通合伙）关于圣湘生物科技股份有限公司非经营性资金占用及其他关联资金往来情况汇总的专项审核报告
Regulatory Filings
2024-04-26 Chinese
圣湘生物科技股份有限公司2023年度独立董事述职报告（乔友林）
Board/Management Information Classification · 95% confidence The document is titled as the "2023年度独立董事述职报告" which translates to "2023 Annual Independent Director's Work Report." It is a detailed report by an independent director about their duties, attendance, and opinions on company governance and operations during the year 2023. The content focuses on the independent director's role, meetings attended, communication with management and shareholders, and evaluation of company practices. It does not contain financial statements or audit results, nor is it an announcement or proxy solicitation. It is a management-related report focusing on governance and director duties rather than a financial report or regulatory filing. Therefore, the most appropriate classification is "Board/Management Information (MANG)" as it relates to board member activities and management information.
2024-04-26 Chinese
圣湘生物科技股份有限公司2023年度环境、社会及公司治理（ESG）报告
Regulatory Filings
2024-04-26 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.